Answers are grounded in this paper and cite their sources.
Fluorescence imaging is sensitive but limited by autofluorescence and poor light penetration. Afterglow imaging reduces background, yet light-activated probes are hard to activate in deep tissues. Ultrasound-activated afterglow uses penetrant ultrasound, but current probes exhibit weak luminescence and lack anatomical reference. We develop Ce6-Gd NPs for dual-modal ultrasound-afterglow and T1-MRI. Ce6 NPs show 23-fold stronger afterglow than bilirubin (BL) NPs, and Gd3+ incorporation further amplifies it by 3-fold, associated with enhanced ROS generation, offering a new strategy to boost ultrasound-induced luminescence. Gd3+ also provides T1 relaxivity 19-fold higher than Gd-DOTA, serving as an efficient MRI contrast agent. Ce6-Gd NPs generate detectable afterglow through 2.5 cm chicken breast and allow repeatable activation. In vivo, local injection enables tumor imaging and MRI contrast, while intravenous injection visualizes abdominal tumors in an orthotopic pancreatic model.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: